Aclaris Therapeutics (ACRS) Set to Release Quarterly Earnings on Thursday

Aclaris Therapeutics (NASDAQ:ACRS) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Aclaris Therapeutics to announce earnings of ($0.16) per share and revenue of $1.27 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. The firm had revenue of $1.63 million during the quarter, compared to the consensus estimate of $1.38 million. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%. On average, analysts expect Aclaris Therapeutics to post ($0.62) EPS for the current fiscal year and ($0.63) EPS for the next fiscal year.

Aclaris Therapeutics Stock Performance

Shares of ACRS opened at $3.74 on Wednesday. Aclaris Therapeutics has a fifty-two week low of $2.10 and a fifty-two week high of $6.60. The company has a market capitalization of $522.93 million, a PE ratio of -6.45 and a beta of 0.96. The stock has a fifty day moving average of $4.78 and a two-hundred day moving average of $4.53.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ACRS shares. Wedbush lowered their target price on shares of Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating for the company in a report on Wednesday, October 28th. Wall Street Zen raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Aclaris Therapeutics in a report on Wednesday, October 28th. Finally, Craig Hallum set a $9.00 price objective on shares of Aclaris Therapeutics in a research note on Wednesday, October 28th. Three analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $11.33.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.